← All trials
NCT06563245
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 25, 2024
- Primary completion
- Nov 15, 2029
- Completion date
- Nov 15, 2039
- First posted
- Aug 20, 2024
- Last posted
- Sep 26, 2024
- Enrollment
- 96
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Children's Cancer Group, ChinaLead sponsor
- Hebei UniversityCollaborator
- Zhengzhou UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Central South UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Jiao Tong UniversityOfficial
- Tianjin Medical UniversityCollaborator
- Tongji UniversityCollaborator
- Sichuan UniversityCollaborator
- Shandong UniversityCollaborator
- Anhui Medical UniversityCollaborator
- Huazhong University of Science and TechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.